Literature DB >> 33221064

Discovery of benzhydrol-oxaborole derivatives as Streptococcus pneumoniae leucyl-tRNA synthetase inhibitors.

Guiyun Hao1, Hao Li2, Fei Yang1, Duoling Dong1, Zezhong Li1, Yingying Ding3, Wei Pan3, Enduo Wang4, Rujuan Liu5, Huchen Zhou6.   

Abstract

Pneumonia caused by bacterium S. pneumoniae is a severe acute respiratory infectious disease with high morbidity and mortality, especially for children and immunity-compromised patients. The emergence of multidrug-resistant S. pneumoniae also presents a challenge to human health. Leucyl-tRNA synthetase (LeuRS) catalyzes the attachment of l-leucine to tRNALeu, which plays an essential role in protein translation and is considered an attractive antimicrobial drug target. In the present work, benzhydrol-oxaborole hybrid compounds were designed and synthesized as inhibitors of S. pneumoniae LeuRS. Exploration of the phenyl ring near Lysine 389 eventually yielded compounds 46 and 54 with submicromolar inhibitory potency. The co-crystal of compound 54 in the editing domain pocket of SpLeuRS was obtained and confirmed the formation of an additional hydrogen bond between the carbonyl of 54 and Lysine 389. It also showed anti-pneumococcal activity in vitro. The structure-activity relationship was discussed. This work will provide an essential foundation for the further development of anti-pneumococcal agents by targeting LeuRS.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-pneumonia; Benzhydrol-Oxaborole; S. pneumonia LeuRS (SpLeuRS); Structure-activity relationship

Mesh:

Substances:

Year:  2020        PMID: 33221064     DOI: 10.1016/j.bmc.2020.115871

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

Review 1.  Aminoacyl-tRNA Synthetases as Valuable Targets for Antimicrobial Drug Discovery.

Authors:  Luping Pang; Stephen D Weeks; Arthur Van Aerschot
Journal:  Int J Mol Sci       Date:  2021-02-10       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.